Top Markets
Coin of the day
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
株式のランク #32696
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
株価
$0.10046734
時価総額
$9.46M
変化(1日)
32.34%
変化(1年)
-21.98%
DE
取引 TME Pharma N.V. (ALTME)

カテゴリー

TME Pharma N.V.(ALTME)の配当利回りの履歴
TME Pharma N.V.(銘柄コード: ALTME)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
TME Pharma N.V.(ALTME)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)